Journals / Turkish Journal of Medical Sciences / 2022 / Cilt: 52 - Sayı: 2

Assessment of Takayasu arteritis in routine practice with PETVAS, an 18F-FDG PET quantitative scoring tool

Pages
313–322
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Although scores in our study (performed at one-h) were lower compared to the original PETVAS study performed at two h, PETVAS seems to be a reliable tool to quantify FDG PET scores in routine practice.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aim: The aim of this study was to evaluate the value of the PET vascular activity score (PETVAS) during the follow-up of patients with Takayasu arteritis.
📊
Key Findings & Data:Materials and methods: Takayasu arteritis patients who underwent 18F-Fluorodeoxyglucose (FDG) PET imaging were evaluated retrospectively.
💡
Conclusion & Impact:Although scores in our study (performed at one-h) were lower compared to the original PETVAS study performed at two h, PETVAS seems to be a reliable tool to quantify FDG PET scores in routine practice.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background/aim: The aim of this study was to evaluate the value of the PET vascular activity score (PETVAS) during the follow-up of patients with Takayasu arteritis. Materials and methods: Takayasu arteritis patients who underwent 18F-Fluorodeoxyglucose (FDG) PET imaging were evaluated retrospectively. In 8 patients both 1 and 2-h imagings were also performed prospectively. For PETVAS, 9 arterial areas were scored between 0-3 according to the FDG uptake. Results: Forty-six images of 34 patients were evaluated. PETVAS was higher in patients with clinically active disease (p = 0.03) and in the C-reactive protein (CRP) elevated group among clinically inactive patients (p = 0.0015). PETVAS correlated with CRP (p = 0.003, r = 0.53) and erythrocyte sedimentation rate (p = 0.005, r = 0.41), whereas age, disease duration, immunosuppressive, and glucocorticoid (GC) treatments were not associated with PETVAS. First vs. 2nd-h PETVAS was similar in patients who had both 1st and 2nd h PET scans (p = 0.67). Conclusion: We observed higher PETVAS in patients with active disease and elevated acute phase reactants. Although scores in our study (performed at one-h) were lower compared to the original PETVAS study performed at two h, PETVAS seems to be a reliable tool to quantify FDG PET scores in routine practice.

🔖

Cite This Article

DİRESKENELİ, H., ÖZGÜVEN, S., ÖNEŞ, T., ERDİL, T. Y., ÖNER, F. A., TAHRA, S. K., ÜNAL, A. U. (2022). Assessment of Takayasu arteritis in routine practice with PETVAS, an 18F-FDG PET quantitative scoring tool. Turkish Journal of Medical Sciences, Cilt: 52 - Sayı: 2, 313–322. https://ajindex.com/articles/609757

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (3)

  1. Direskeneli H, Aydin SZ, Merkel PA. Assessment of disease activity and progression in Takayasu’s arteritis. Clinical and Experimental Rheumatology 2011; 29(1 Suppl 64): S86-91
  2. Dejaco C, Ramiro S, Duftner C, Besson FL, Bley TA et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. Annals of the Rheumatic Diseases 2018; 77(5): 636-643. doi:10.1136/annrheumdis-2017-212649 3. Danve A, O’Dell J. The Role of 18F Fluorodeoxyglucose Positron Emission Tomography Scanning in the Diagnosis and Management of Systemic Vasculitis. International Journal of Rheumatic Diseases 2015; 18(7): 714-24. doi:10.1111/1756- 185X.12713 4. Walter MA, Melzer RA, Schindler C, Muller-Brand J, Tyndall A et al. The value of [18F]FDG-PET in the diagnosis of largevessel vasculitis and the assessment of activity and extent of disease. European Journal of Nuclear Medicine and Molecular Imaging 2005; 32(6): 674-81. doi:10.1007/s00259-004-1757-9 5. Lee YH, Choi SJ, Ji JD, Song GG. Diagnostic accuracy of 18F-FDG PET or PET/CT for large vessel vasculitis: A metaanalysis. Zeitschrift für Rheumatologie 2016; 75(9): 924-931. doi:10.1007/s00393-015-1674-2 6. Soussan M, Nicolas P, Schramm C, Katsahian S, Pop G et al. Management of large-vessel vasculitis with FDGPET: a systematic literature review and meta-analysis. Medicine (Baltimore), 2015; 94(14): e622. doi:10.1097/ MD.0000000000000622 7. Cheng Y, Lv N, Wang Z, Chen B, Dang A. 18-FDG-PET in assessing disease activity in Takayasu arteritis: a meta-analysis. Clinical and Experimental Rheumatology 2013; 31(1 Suppl 75): S22-7
  3. Slart RHJA, Writing group., Reviewer group et al. FDG-PET/ CT(A) imaging in large vessel vasculitis and polymyalgia rheumatica: joint procedural recommendation of the EANM, SNMMI, and the PET Interest Group (PIG), and endorsed by the ASNC. FDG-PET/CT(A) imaging in large vessel vasculitis and polymyalgia rheumatica: joint procedural recommendation of the EANM, SNMMI, and the PET Interest Group (PIG), and endorsed by the ASNC. European Journal of Nuclear Medicine and Molecular Imaging 2018; 45(7): 1250- 1269. doi:10.1007/s00259-018-3973-8 9. Bucerius J, Mani V, Moncrieff C, Machac J, Fuster V et al. Optimizing 18F-FDG PET/CT imaging of vessel wall inflammation: the impact of 18F-FDG circulation time, injected dose, uptake parameters, and fasting blood glucose levels. European Journal of Nuclear Medicine and Molecular Imaging 2014; 41(2): 369-83. doi:10.1007/s00259-013-2569-6